GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Equity-to-Asset

WuXi Biologics (Cayman) (FRA:1FW2) Equity-to-Asset : 0.72 (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. WuXi Biologics (Cayman)'s Total Stockholders Equity for the quarter that ended in Jun. 2023 was €4,864 Mil. WuXi Biologics (Cayman)'s Total Assets for the quarter that ended in Jun. 2023 was €6,720 Mil. Therefore, WuXi Biologics (Cayman)'s Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.72.

The historical rank and industry rank for WuXi Biologics (Cayman)'s Equity-to-Asset or its related term are showing as below:

FRA:1FW2' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11   Med: 0.73   Max: 0.88
Current: 0.71

During the past 10 years, the highest Equity to Asset Ratio of WuXi Biologics (Cayman) was 0.88. The lowest was 0.11. And the median was 0.73.

FRA:1FW2's Equity-to-Asset is ranked better than
55.72% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:1FW2: 0.71

WuXi Biologics (Cayman) Equity-to-Asset Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Equity-to-Asset Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.71 0.73 0.71 0.71

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.73 0.71 0.72 0.71

Competitive Comparison of WuXi Biologics (Cayman)'s Equity-to-Asset

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Equity-to-Asset falls into.



WuXi Biologics (Cayman) Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

WuXi Biologics (Cayman)'s Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=4745.579/6711.244
=0.71

WuXi Biologics (Cayman)'s Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=4863.926/6720.244
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (FRA:1FW2) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


WuXi Biologics (Cayman) Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines